

Cite this: DOI: 10.1039/c2gc36378j

www.rsc.org/greenchem

Replacement of dichloromethane within chromatographic purification: a guide to alternative solvents†‡

Donna S. MacMillan,^a Jane Murray,^b Helen F. Sneddon,^c Craig Jamieson^a and Allan J. B. Watson^{*a}

Received 30th August 2012, Accepted 28th September 2012

DOI: 10.1039/c2gc36378j

Replacement of dichloromethane as the bulk medium within chromatographic purification has been evaluated with a broad range of molecules containing functionality common within Medicinal Chemistry programmes. Analysis of the data set has generated a set of general guidelines to assist in the selection of alternative solvents for CH₂Cl₂ as the bulk media in these ubiquitously employed processes.

Replacement of hazardous solvents in order to achieve greater sustainability and/or to reduce both environmental and operational costs is a key emerging consideration within the pharmaceutical industry.¹ A number of reports have recently emerged from leading pharmaceutical companies detailing the drivers and requirements for increasing the sustainability of their overall processes through adoption of green chemistry principles and, indeed, have signposted a change in solvent selection as a primary method of achieving this.^{1–3} In particular, chlorinated solvents such as CH₂Cl₂ and CHCl₃ are two common solvents of routine and widespread use that possess significant hazardous toxicity to both humans and the environment and which require more careful and costly disposal.⁴ Consequently, there is a strong desire to supplant these systems with more benign alternatives.

In relation to this, purification is by far the largest consumer of solvent within any synthetically aligned research programme. Indeed in the context of pharmaceutical research, on average solvent has been estimated to constitute some 56% of the total material used to manufacture active pharmaceutical ingredients.^{2a} Accordingly, moving to a more environmentally conservative solvent selection within chromatographic purification could therefore be expected to have the largest single impact on the overall sustainability of chemical synthesis endeavours.

However, while this may seem reasonably straightforward in principle, the lack of solid data in this area presents a barrier to the general adoption of these more environmentally acceptable approaches.

Equielutropic series have been constructed for a range of conventional solvents,⁵ however, these are heavily skewed towards solvents with major regulatory and/or toxicological issues, for example chlorinated, toluene, hexane. This is presumably due to sustainability not being a primary concern during the time period in which this analysis was conducted (in the 1960s). As such, little equivalent data exists for alternative solvents with fewer issues that can be employed as replacements.

Having said this, a very recent contribution in this area from Amgen has endeavoured to provide a guide to alternative solvent selection for replacement of CH₂Cl₂ in purification.³ This excellent study has focused on the use of alcohol-(MeOH, EtOH, i-PrOH) and additive-modified (AcOH, NH₄OH) mixtures of heptanes, EtOAc, and *tert*-butyl methyl ether (TBME) for the purification of a range of 26 drug-like molecules and has presented a modern equielutropic series based on these mixtures in comparison to MeOH–CH₂Cl₂.

In a complementary approach, we recently sought to generate specific and comprehensive data to assist in the selection of alternative solvents as replacements for CH₂Cl₂ within chromatographic purification using binary eluent systems. The current study will greatly assist in the selection of greener alternative eluents and we believe will help facilitate widespread adoption of more sustainable eluents in chromatographic purification processes.

Results and discussion

Methods

Our approach towards identifying potential replacements for chlorinated solvents, particularly CH₂Cl₂, in purification was based on thin layer chromatography (TLC) analysis. This was similar to the approach taken by Neher in 1964 (the approach that led to the original equielutropic series)⁵ and to that recently adopted by Amgen.³ To ensure the greatest opportunity for adoption of any developed method, we focused primarily on binary eluent mixtures comprising of a bulk solvent modified by MeOH (or *i*-PrOH, *vide infra*) as we believed that these would be more convenient to the practicing chemist. Each compound from our selected library would be analysed by TLC at various

^aDepartment of Pure and Applied Chemistry, WestCHEM, University of Strathclyde, Thomas Graham Building, 295 Cathedral Street, Glasgow, G1 1XL, UK. E-mail: allan.watson.100@strath.ac.uk; Fax: +44 (0)141 548 4822; Tel: +44 (0)141 548 2439


^bSigma-Aldrich, The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT, UK

^cGreen Chemistry Performance Unit, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

†Dedicated to Professor William J. Kerr on the occasion of his 50th birthday.

‡Electronic supplementary information (ESI) available: Calculated molecular properties of all compounds, graphs for *R_f* vs. % modifier for each bulk solvent, box plot analyses, and Spotfire analyses. See DOI: 10.1039/c2gc36378j

Set 1: Fragment-like Moieties



Set 2: Drug-like Molecules




Fig. 1 Compound library evaluated.†

compositions of modifier:bulk medium with analyses performed in triplicate to ensure reproducibility.

To initiate our study, we first selected a range of small lead-like molecules that displayed broad coverage of the functional group landscape. In addition to this and in attempts to ensure our data was as applicable and relevant as possible, we also selected a range of structurally more complex molecules, several of which were previously marketed drug molecules and others which had been prepared as part of on-going academic medicinal chemistry projects.⁶ In total, we surveyed 95 compounds – 74 fragment-like moieties and 21 larger, drug-related molecules (sets 1 and 2, respectively, Fig. 1).

To ensure our data set was as realistic and as representative as possible, we performed principal component analysis (PCA) of the 95 compounds based on six descriptors:⁷ (i) molecular weight (94–822); (ii) number of hydrogen bond donors (0–6); (iii) number of hydrogen bond acceptors (0–12); (iv) number of rotatable bonds (0–14); (v) XlogP (–1.7 to 3.2); and (vi) polar surface area (12–220 Å²). A scatter diagram of this analysis (Fig. 2) clearly suggests diverse coverage of the chemical landscape: the *x*-axis (PCA dimension 0) is mainly a function of molecular weight and polar descriptors while the *y*-axis (PCA dimension 1) is mainly a lipophilicity descriptor. Inspection of the data suggests that there is a slight bias for the lower




Fig. 2 PCA of the 95-substrate set.†

molecular weight side of the scatter graph. This is likely to be a consequence of the majority of low molecular weight compounds (63 compounds in the molecular weight range 94–221), although, having stated this, there is still an excellent distribution of molecular properties within the data set and these compounds are more likely to be of relevance within a pharmaceutical research and development setting.

In terms of the alternative bulk media, we decided to employ several emerging or existing solvents to use in conjunction with the modifier. Specifically, we evaluated cyclopentyl methyl ether (CPME),⁸ TBME, 2-methyl tetrahydrofuran (2-MeTHF), dimethyl carbonate (DMC), and EtOAc. For the modifier, with the exception of EtOAc, we elected to use MeOH as it is one of the most widely used modifiers for polar compound chromatography and would enable a direct comparison with MeOH–CH₂Cl₂ mixtures. For EtOAc, i-PrOH was employed as the modifier based on emerging and promising data for this binary eluent.⁹ In addition, the Amgen group assessed MeOH–EtOAc mixtures in their recent study and had compared this to MeOH–CH₂Cl₂.³ Overall, this would provide five different binary eluent systems to compare with MeOH–CH₂Cl₂ mixtures.

Analysis

A representative combined chart with R_f plotted against % modifier for each of the six solvent systems for compound **89** is shown in Fig. 3. Equivalent data was generated for all 95 compounds with the associated error in average R_f values remaining consistently very low. We also observed reliably excellent linear correlation throughout the data sets, with R^2 values of >0.95.

With the data in hand, we sought to establish trends with which to form the basis for guidelines to direct use of these alternative eluent systems. A useful analysis of the data set was achieved through a simple box plot. Fig. 4 shows a box plot of R_f (y-axis) vs. 10% modifier in each of the bulk media (Table 1 displays the R_f ranges and medians for each eluent). We also conducted the same box plot analysis for the 5% and 20% modifier levels and achieved similar distributions. This analysis gives a usefully condensed assessment of the R_f data for each of the eluent mixtures. The relative distribution of the data for the 95 compounds and for each of the binary mixtures can be clearly




Fig. 3 Illustrative graph of eluent evaluation.‡




Fig. 4 Box plot analysis of R_f vs. eluent at 10% modifier level.‡

Table 1 R_f ranges and medians for box plot analysis in Fig. 4^{†‡}

| Entry | Eluent | R_f range | Median |
|-------|--------------------------------------|-------------|--------|
| 1 | MeOH–CH ₂ Cl ₂ | 0.01–0.88 | 0.41 |
| 2 | MeOH–CPME | 0.02–0.94 | 0.50 |
| 3 | MeOH–TBME | 0.02–0.75 | 0.53 |
| 4 | MeOH–2-MeTHF | 0.06–0.80 | 0.65 |
| 5 | MeOH–DMC | 0.04–0.88 | 0.55 |
| 6 | i-PrOH–EtOAc | 0.02–0.84 | 0.49 |

[†] 10% modifier in bulk solvent.

seen: each of the four quadrants indicates that 25% of the compounds can be found within that particular R_f range.

Firstly, the data for MeOH–CH₂Cl₂ was spread reasonably well and with relatively good quadrant consistency over the R_f range: each of the data quadrants was of comparable magnitude and the data range covers the R_f range 0.01–88, although there was a noted slight bias for the lower end of the R_f range (median R_f = 0.41). Comparing the data for the other five alternative eluent systems, the following observations can be made: (i) The data for the CPME-based system was excellent and, in fact, this analysis suggests that the CPME data is actually superior to the CH₂Cl₂ system, as the quadrants were more homogenous (median = R_f 0.50) and the dynamic R_f range was wider




Fig. 5 Spotfire analysis of MeOH–CH₂Cl₂ data vs. MeOH–CPME data at 10% modifier.‡

(0.02–0.94). This may translate to an improved achievable chromatographic resolution with the CPME-based eluent when employed in a purification scenario. (ii) Both the TBME- and 2-MeTHF-based eluents have comparatively greater compression in their data sets. For example, for 2-MeTHF, 50% of the total data is found in the 0.65–0.80 R_f range. This truncation of the higher R_f quadrants (median R_f = 0.53 and 0.65, respectively) suggests a lower utility for replacing CH₂Cl₂ and, in addition, the reduced R_f range (0.02–0.75 and 0.06–0.80, respectively) suggests resolution is likely to be poorer. (iii) The DMC and EtOAc data also established excellent distribution with good R_f range coverage (0.04–0.88 and 0.02–0.84, respectively) and good homogeneity of the data sets (median R_f = 0.55 and 0.49, respectively). Overall, based on this analysis it would appear that MeOH–CPME offers the highest potential for replacement of MeOH–CH₂Cl₂ in this context, however, MeOH–DMC and i-PrOH–EtOAc are also likely to offer considerable utility.

Based on the box plot analysis above, we sought to further analyse our data in order to establish if more in depth correlations existed between the selected replacement solvents and CH₂Cl₂. Accordingly, we employed Spotfire¹⁰ to survey our data for relationships between the data sets for each binary eluent system. This analysis revealed even stronger support for CPME as a candidate for replacement of CH₂Cl₂. Fig. 5 shows how the data for MeOH–CH₂Cl₂ correlates with the data for MeOH–CPME at the 10% modifier level.

We were pleased to note a strong correlation between the data sets from this analysis with an R^2 of 0.71. Similar trends were observed for the 5% and 20% modifier data sets (R^2 = 0.55 and 0.65, respectively). Interestingly, as shown in Fig. 5, the majority of outliers were acidic in nature, for example compounds **5**, **10**, **20**, **37**, **86**, and **91**. An additional trend was observed for the acidic compounds where, in general and over the entire data set, these seem to run to higher R_f in MeOH–CPME mixtures than in equivalent MeOH–CH₂Cl₂ mixtures. By contrast, certain amine derivatives, for example compounds **66**, **79**, **93**, and **95**, exhibited lower R_f values in the MeOH–CPME eluent as compared to MeOH–CH₂Cl₂. As predicted from the box plot analysis, similar Spotfire-based mining of the other alternative eluents revealed much poorer correlation with the MeOH–CH₂Cl₂ data

and, accordingly, these are less likely to function effectively as direct replacements for CH₂Cl₂.‡ Based on all of the above, we believe that MeOH–CPME is a potential viable replacement for MeOH–CH₂Cl₂ within chromatographic purification.

Conclusions

In summary, we have evaluated several alternative solvents as potential replacements for CH₂Cl₂ as the bulk medium for chromatographic purification of a broad range of polar fragments and more complex molecules with functionality frequently encountered within Medicinal Chemistry programmes. Overall, we have established several general trends that may assist in the replacement of CH₂Cl₂ in MeOH-based purification processes. Specifically, based on our general analysis of the whole data set, CPME would appear to offer considerable potential as a direct replacement for CH₂Cl₂ in binary eluents using MeOH as the modifier with MeOH–DMC and i-PrOH–EtOAc also offering some potential advantages. We have also observed some intriguing trends in relation to certain acidic and basic compounds, which may be useful to laboratory practitioners. Overall, based on the work detailed here and related emerging studies, we believe that replacement of CH₂Cl₂ would not only be possible but also practical, straightforward, and highly beneficial for sustainable practice in industry and academia.

Acknowledgements

We are grateful to GlaxoSmithKline and Sigma Aldrich for the kind donation of consumables. DSM wishes to thank the University of Strathclyde Knowledge Transfer Account for postdoctoral funding. Graham Inglis and Dr Simon MacDonald (GSK) are thanked for helpful discussions.

Notes and references

- R. K. Henderson, C. Jiménez-González, D. J. C. Constable, S. R. Alston, G. G. A. Inglis, G. Fisher, J. Sherwood, S. P. Binks and A. D. Curzons, *Green Chem.*, 2011, **13**, 854.
- (a) D. J. C. Constable, C. Jiménez-González and R. K. Henderson, *Org. Process Res. Dev.*, 2007, **11**, 133; (b) K. Alfonsi, J. Colberg, P. J. Dunn, T. Fevig, S. Jennings, T. A. Johnson, H. P. Kleine, C. Knight, M. A. Nagy, D. A. Perry and M. Stefaniak, *Green Chem.*, 2008, **10**, 31; (c) B. W. Cue and J. Zhang, *Green Chem. Lett. Rev.*, 2009, **2**, 193; (d) T. W. J. Cooper, I. B. Campbell and S. J. F. MacDonald, *Angew. Chem., Int. Ed.*, 2010, **49**, 8082.
- J. P. Taygerly, L. M. Miller, A. Yee and E. A. Peterson, *Green Chem.*, 2012, DOI: 10.1039/c2gc36064k.
- (a) G. S. Cooper, A. S. Bale and P. Schlosser, *Toxicological Review of Dichloromethane*, US EPA, 2011, <http://www.epa.gov/iris/toxreviews/0070tr.pdf>; (b) http://epa.gov/chemfacts/s_dcm.txt; (c) MSDS available at <http://www.sigmaaldrich.com>
- R. Neher, in *Thin Layer Chromatography*, ed. G. B. Marini-Bettolo, Elsevier, Amsterdam, 1964, p. 77.
- Compounds **83**, **94**, and **95** were kindly donated by Professor C. J. Suckling, University of Strathclyde, Glasgow, UK.
- The KNIME program was used to establish the PCA descriptors. This is freely available online at www.knime.org. For further information, see the ESI.‡
- For information on the use of CPME, see: (a) K. Watanabe, N. Yamagiwa and Y. Torisawa, *Org. Process Res. Dev.*, 2007, **11**, 251; (b) http://www.zeon.co.jp/business_e/enterprise/spechemi/spechemi5-13.html
- A. J. B. Watson, Unpublished results.
- <http://spotfire.tibco.com/>